All In Biotech

NDA 213736 · Incyte Corp

Pemazyre

Pemigatinib · Oral · Kinase Inhibitor

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Aug 26, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Apr 17, 2020

Approved uses

2

Original approval plus efficacy supplements

Registered trials

51

1 Phase 3, 13 recruiting

FAERS reports

853

532 serious, 150 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 9, 2026.

PEMAZYRE is a kinase inhibitor indicated: for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. ( 1 , 2.1 ) This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 , 2.1 ) For the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. ( 1 , 2.1 ) 1.1 Cholangiocarcinoma PEMAZYRE is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test [see Dosage and Administration ( 2.1 )] . This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies ( 14.1 )]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 1.2 Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement PEMAZYRE is indicated for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement.

Mechanism: Pemigatinib is a small molecule kinase inhibitor that targets FGFR1, 2 and 3 with IC 50 values of less than 2 nM. Pemigatinib also inhibited FGFR4 in vitro at a concentration approximately 100 times higher than those that inhibit FGFR1, 2, and 3. Pemigatinib inhibited FGFR1-3 phosphorylation and signaling and decreased cell viability in cancer cell lines with activating FGFR amplifications and fusions that resulted in constitutive activation of FGFR signaling. Constitutive FGFR signaling can support the proliferation and survival of malignant cells. Pemigatinib exhibited anti-tumor activity...

Therapeutic areas: Oncology · Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 26, 2022 Supplement 2 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • Apr 17, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
3 products under this application
  • PEMAZYRE · PEMIGATINIB 13.5MG · TABLET, ORAL · Prescription
  • PEMAZYRE · PEMIGATINIB 4.5MG · TABLET, ORAL · Prescription
  • PEMAZYRE · PEMIGATINIB 9MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pemigatinib" as an intervention, any sponsor and status, largest first.

All 51 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use155
  • disease progression144
  • death86
  • fatigue82
  • alopecia67
  • cholangiocarcinoma62
  • hyperphosphataemia54
  • drug ineffective48
  • diarrhoea46
  • nausea43
  • constipation40
  • hospitalisation40

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2020101
202189
202266
2023279
2024123
202595
2026100

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Pemazyre (Pemigatinib)

2024 spending

$29.5M

Beneficiaries

221

1,481 claims

Per beneficiary

$133,629

$1,327.70 per unit

View as table
YearSpending
2020$6,305,282
2021$19,119,498
2022$25,659,299
2023$26,255,018
2024$29,532,057

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 21 on PubMed

Sponsor: Incyte

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.